12d • General discussion
Cardiogen: The Heart-Targeted Bioregulator Built for Cardiac Longevity Research
❇️ The heart beats roughly 100,000 times a day for a lifetime — and like every other organ, its capacity to repair and maintain itself declines with age. Cardiogen is a cardiac-specific peptide bioregulator from the Khavinson series designed to address exactly that. With research touching on ischemic protection, cardiomyocyte preservation, and anti-fibrotic signaling, it's one of the more compelling compounds for anyone studying cardiovascular aging.
❇️ What Is Cardiogen?
Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg / AEDR) developed at the St. Petersburg Institute of Bioregulation and Gerontology. Like all Khavinson bioregulators, it was designed to be tissue-specific — in this case targeting myocardial (heart muscle) cells. The compound is thought to work by binding to chromatin in cardiac cells and modulating gene transcription, promoting the expression of proteins involved in cellular repair, stress resistance, and structural integrity of the myocardium.
The heart is predominantly made up of terminally differentiated cells — cardiomyocytes that can't easily be replaced once lost. This makes the preservation of existing cardiac tissue especially important, and it's the core rationale behind Cardiogen's research focus.
🔬 Key Research Findings
Preclinical studies on Cardiogen and related cardiac bioregulators have produced meaningful data across several areas:
• Cardioprotection in ischemia-reperfusion models: Research in animal models showed that pre-treatment with cardiac peptide bioregulators significantly reduced cardiomyocyte death following ischemia-reperfusion injury — the type of damage that occurs during a heart attack and its aftermath.
• Reduced cardiomyocyte apoptosis: Cardiogen has been shown to downregulate apoptotic signaling in cardiac tissue under stress conditions, helping preserve the limited pool of functional heart muscle cells.
• Anti-fibrotic signaling: Cardiac fibrosis — the replacement of functional muscle with scar tissue — is a hallmark of aging and post-injury remodeling. Studies suggest Cardiogen may help reduce fibrotic marker expression in myocardial tissue.
• Antioxidant defense in cardiac tissue: The heart has an exceptionally high metabolic rate and generates significant oxidative byproducts. Cardiogen has been associated with upregulation of antioxidant enzymes (SOD, catalase) specifically in cardiac tissue, mirroring findings seen across the bioregulator series.
• Improved heart rate variability markers in aging models: Some research has pointed to improved autonomic cardiac regulation in older animal subjects following bioregulator treatment, suggesting preserved electrophysiological function alongside structural benefits.
❇️ How It Compares to Other Cardiac Peptides
Cardiogen operates at a fundamentally different level than better-known cardiac peptides like BPC-157, which works through nitric oxide pathways and growth factor signaling to promote angiogenesis and tissue repair. BPC-157 is broader in scope and faster-acting in acute injury models. Cardiogen is slower and more targeted — it's a gene-level intervention aimed at the myocardium specifically, better suited to long-term maintenance and aging prevention than acute repair. They're complementary rather than competitive, and some longevity protocols include both.
🧬 Research Protocols
The following reflects parameters used in research and investigational settings:
• Typical studied dose range: 5–10 mg per day, consistent with the broader Khavinson bioregulator class. Higher doses up to 20 mg have been used in some investigational applications.
• Frequency: Once daily. No strong rationale for split dosing given the gene-expression level mechanism and relatively long intracellular action window.
• Route of administration: Subcutaneous injection in most published research. Oral enteric-coated formulations exist within the bioregulator product line, with subcutaneous delivery generally preferred for reliable systemic exposure.
• Cycle length: 10–20 consecutive days per cycle, repeated 1–2 times per year in longevity-focused protocols. Some cardiovascular-specific models use more frequent cycling (quarterly) given the high metabolic burden on cardiac tissue.
• Stacking notes: Commonly paired with Ventfort (vascular bioregulator) in cardiovascular longevity protocols — Cardiogen targeting the myocardium while Ventfort supports vessel wall integrity. BPC-157 is sometimes included for its complementary angiogenic and anti-inflammatory effects. Thymalin (immune support) and Epithalon (telomere/anti-aging) round out many comprehensive protocols.
✅Bottom Line
Cardiogen addresses one of the most fundamental challenges in aging biology: the heart can't regenerate what it loses. By working at the gene expression level to preserve and protect existing cardiomyocytes, reduce fibrosis, and bolster antioxidant defenses, it represents a thoughtful approach to cardiac longevity research. For researchers building multi-organ bioregulator protocols, it's an essential piece of the cardiovascular puzzle.
⚠️This article is for educational purposes only. All compounds discussed are for research use only and are not approved for human use. Nothing in this article constitutes medical advice. Always consult a licensed healthcare professional before making any health decisions.
0
0 comments
Cardiogen: The Heart-Targeted Bioregulator Built for Cardiac Longevity Research
powered by
skool.com/peptide-resource-center-3431
We are here for you because we've been there. Get support, education, resources and more!!!
Suggested communities
Powered by